Jacob Van Naarden
Eli Lilly's new cancer R&D chief has some things to say about drug discovery, the difficulty in finding new drugs to buy and the Venn dilemma
Josh Bilenker’s abrupt exit from the top job at Loxo Oncology at Lilly on Friday came as a surprise to many. But then everything …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
